CollPlant Biotechnologies Ltd
Company Profile
Business description
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
Contact
4 Oppenheimer Street
P.O. Box 4132, Weizmann Science Park
Rehovot7670104
ISRT: +972 732325600
E: mcarey@RxIR.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
73
Stocks News & Analysis
video
Can this fallen ASX star shine again?
stocks
Ask the analyst: Are Telix's growth prospects priced in?
stocks
How to build an income portfolio
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,529.50 | 38.00 | 0.45% |
| CAC 40 | 7,602.06 | 24.17 | 0.32% |
| DAX 40 | 19,508.29 | 134.46 | 0.69% |
| Dow JONES (US) | 43,041.35 | 177.49 | 0.41% |
| FTSE 100 | 8,292.66 | 39.01 | 0.47% |
| HKSE | 21,092.87 | 159.11 | -0.75% |
| NASDAQ | 18,505.46 | 162.52 | 0.89% |
| Nikkei 225 | 39,605.80 | 224.91 | 0.57% |
| NZX 50 Index | 12,766.75 | 78.89 | -0.61% |
| S&P 500 | 5,857.79 | 42.76 | 0.74% |
| S&P/ASX 200 | 8,252.80 | 38.30 | 0.47% |
| SSE Composite Index | 3,284.32 | 66.58 | 2.07% |